



## **SomnoMed exceeds 150,000 patients worldwide**

**21st November 2013**, SomnoMed Limited (ASX:SOM) announced today that it had exceeded the benchmark of 150,000 patients worldwide fitted with a SomnoDent® device.

“It is with pleasure that we announce that in November 2013 SomnoMed exceeded 150,000 patients fitted with a SomnoDent® device worldwide. In July 2012, only 16 months ago, we announced that SomnoMed had reached the milestone of 100,000 patients,” said Dr. Peter Neustadt, Executive Chairman of SomnoMed.

“It is a great sign of the growing acceptance of COAT™ – Continuous Open Airway Therapy, which is increasingly becoming an accepted treatment alternative to CPAP for sleep disordered patients, and the global success of our SomnoDent® products. Whilst it took eight years to reach 100,000 patients, it only took 16 months to exceed the 150,000 mark,” commented Dr. Neustadt.

Of the patients treated 90,000 patients reside in the USA/Canada, over 36,000 in Europe, with the balance in the Asia-Pacific region.

Over the last fifteen months, SomnoMed implemented a medically oriented strategy focusing on growing the acceptance of COAT™ and the SomnoDent® device with medical specialists, increasing the referrals of these physicians to SomnoMed network dentists and on building direct relationships with insurers, IDNs and HMOs.

“The launch of an electronic compliance chip embedded in our SomnoDent® devices from beginning 2014 is a further step in addressing the demands of medical practitioners and insurers. It allows the physician to control the patient throughout the life time treatment of his or her chronic condition and delivers facts when it comes to nightly treatment compliance of the patient. Compliance is the key to patient’s ongoing treatment and wellbeing. It is the major issue when it comes to the alternative CPAP treatment, which leaves a significant percentage of patients only partially treated or not treated at all,” said Dr. Neustadt.

**Contact:** Dr. Peter Neustadt – Executive Chairman, SomnoMed Limited

Ph +61 2 9467 0400 or +61 (0) 414 566 592-m

### **About SomnoMed**

SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent® is the most comfortable and effective design and treatment solution for over 150,000 patients in 22 countries.

For additional information, visit SomnoMed at <http://www.somnomed.com.au>